ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

Maximilian Pallauf, Director of the Bladder Cancer Program, Salzburg Regional Hospitals (SALK)

“Our patients should benefit from medical innovations at the earliest possible stage and receive treatment tailored to their specific disease. Through our Bladder Cancer Program, we bring together specialized clinical care and scientific expertise to achieve this goal.”

Lukas Lusuardi, Head of the Department of Urology and Andrology, Salzburg University Hospital of the Salzburg Regional Hospitals (SALK)

“Our patients should benefit from medical innovations at the earliest possible stage and receive treatment tailored to their specific disease. Through our Bladder Cancer Program, we bring together specialized clinical care and scientific expertise to achieve this goal.”

Maximilian Pallauf, Director of the Bladder Cancer Program, Salzburg Regional Hospitals (SALK)

“Being the first center in Europe to administer ANKTIVA for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer highlights our pioneering role in translating novel therapeutic approaches into routine clinical practice.”

Lukas Lusuardi, Head of the Department of Urology and Andrology, Salzburg University Hospital of the Salzburg Regional Hospitals (SALK)

“Being the first center in Europe to administer ANKTIVA for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer highlights our pioneering role in translating novel therapeutic approaches into routine clinical practice.”

Richard Adcock, President and Chief Executive Officer of ImmunityBio

“Our patients should benefit from medical innovations at the earliest possible stage and receive treatment tailored to their specific disease. Through our Bladder Cancer Program, we bring together specialized clinical care and scientific expertise to achieve this goal.”

Paul Tredwell, Global Chief Executive Officer of Accord Healthcare

“We are delighted to see the first patients in Europe receive ANKTIVA, marking an important step for those seeking additional treatment options.”

Brian O’Shaughnessy, Chief Commercial Officer at Uniphar

“This partnership reinforces Uniphar’s role as a trusted international partner for biotechnology companies bringing highly specialized therapies to patients across complex markets.”

Brian O’Shaughnessy, Chief Commercial Officer at Uniphar

“By combining our regulatory, quality, supply chain, distribution, and order-to-cash capabilities, we can support ImmunityBio with a scalable platform that enables launch readiness and ongoing commercial supply for ANKTIVA.”